FDG-PET reveals improved cardiac regeneration and attenuated adverse remodelling following Sitagliptin + G-CSF therapy after acute myocardial infarction

Eur Heart J Cardiovasc Imaging. 2016 Feb;17(2):136-45. doi: 10.1093/ehjci/jev237. Epub 2015 Sep 28.

Abstract

Aims: Dual therapy comprising G-CSF for mobilization of bone marrow-derived progenitor cells (BMPCs), with simultaneous pharmacological inhibition of dipeptidylpeptidase-IV for enhanced myocardial recruitment of circulating BMPC via the SDF-1α/CXCR4-axis, has been shown to improve survival after acute myocardial infarction (AMI). Using an innovative method to provide non-invasive serial in vivo measurements and information on metabolic processes, we aimed to substantiate the possible effects of this therapeutic concept on cardiac remodelling after AMI using 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography (FDG-PET).

Methods and results: AMI was induced in C57BL/6 mice by performing surgical ligation of the left anterior descending artery in these mice. Animals were then treated with granulocyte-colony stimulating factor + Sitagliptin (GS) or placebo for a duration of 5 days following AMI. From serial PET scans, we verified that the infarct size in GS-treated mice (n = 13) was significantly reduced at Day 30 after AMI when compared with the mice receiving placebo (n = 10). Analyses showed a normalized FDG uptake on Day 6 in GS-treated mice, indicating an attenuation of the cardiac inflammatory response to AMI in treated animals. Furthermore, flow cytometry showed a significant increase in the anti-inflammatory M2-macrophages subpopulation in GS-treated animals. In comparing GS treated with placebo animals, those receiving GS-therapy showed a reduction in myocardial hypertrophy and left ventricular dilatation, which indicates the beneficial effect of GS treatment on cardiac remodelling. Remarkably, flow cytometry and immunohistochemistry showed an increase of myocardial c-kit positive cells in treated mice (n = 12 in both groups).

Conclusion: Using the innovative method of micro-PET for non-invasive serial in vivo measurements of metabolic myocardial processes in mice, we were able to provide mechanistic evidence that GS therapy improves cardiac regeneration and reduces adverse remodelling after AMI.

Keywords: C-kit; G-CSF; Sitagliptin; acute myocardial infarction; cardiac remodelling; positron emission tomography.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Marrow Cells / drug effects
  • Disease Models, Animal
  • Drug Therapy, Combination
  • Fluorodeoxyglucose F18
  • Granulocyte Colony-Stimulating Factor / pharmacology*
  • Humans
  • Mice
  • Mice, Inbred C57BL
  • Myocardial Infarction / diagnostic imaging*
  • Myocardial Infarction / drug therapy*
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals
  • Regeneration / drug effects
  • Sitagliptin Phosphate / pharmacology*
  • Ventricular Remodeling / drug effects

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
  • Granulocyte Colony-Stimulating Factor
  • Sitagliptin Phosphate